{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:49:09Z","timestamp":1792705749987,"version":"4.5.0"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Graves\u2019 disease is an autoimmune disorder caused by auto-antibodies against the thyroid stimulating hormone receptor (TSHR). Overstimulation of the TSHR induces hyperthyroidism and thyroid eye disease (TED) as the most common extra thyroidal manifestation of Graves\u2019 disease. In TED, the TSHR cross talks with the insulin-like growth factor 1 receptor (IGF-1R) in orbital fibroblasts leading to inflammation, deposition of hyaluronan and adipogenesis. The bone marrow may play an important role in autoimmune diseases, but its role in Graves\u2019 disease and TED is unknown. Here, we investigated whether induction of experimental Graves\u2019 disease and accompanying TED involves bone marrow activation and whether interference with IGF-1R signaling prevents this activation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Immunization of mice with TSHR resulted in an increase the numbers of CD4-positive T-lymphocytes (p \u22640.0001), which was normalized by linsitinib (p = 0.0029), an increase of CD19-positive B-lymphocytes (p= 0.0018), which was unaffected by linsitinib and a decrease of GR1-positive cells (p= 0.0038), which was prevented by linsitinib (p= 0.0027). In addition, we observed an increase of Sca-1 positive hematopietic stem cells (p= 0.0007) and of stromal cell-derived factor 1 (SDF-1) (p \u22640.0001) after immunization with TSHR which was prevented by linsitinib (Sca-1: p= 0.0008, SDF-1: p \u22640.0001). TSHR-immunization also resulted in upregulation of CCL-5, IL-6 and osteopontin (all p \u22640.0001) and a concomitant decrease of the immune-inhibitory cytokines IL-10 (p= 0.0064) and PGE2 (p \u22640.0001) in the bone marrow (all p\u2264 0.0001). Treatment with the IGF-1R antagonist linsitinib blocked these events (all p \u22640.0001). We further demonstrate a down-regulation of arginase-1 expression (p= 0.0005) in the bone marrow in TSHR immunized mice, with a concomitant increase of local arginine (p \u22640.0001). Linsitinib induces an upregulation of arginase-1 resulting in low arginase levels in the bone marrow. Reconstitution of arginine in bone marrow cells <jats:italic>in vitro<\/jats:italic> prevented immune-inhibition by linsitinib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Collectively, these data indicate that the bone marrow is activated in experimental Graves\u2019 disease and TED, which is prevented by linsitinib. Linsitinib-mediated immune-inhibition is mediated, at least in part, by arginase-1 up-regulation, consumption of arginine and thereby immune inhibition.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1252727","type":"journal-article","created":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T03:12:06Z","timestamp":1695611526000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Potential involvement of the bone marrow in experimental Graves\u2019 disease and thyroid eye disease"],"prefix":"10.3389","volume":"14","author":[{"given":"Anne","family":"Gulbins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareike","family":"Horstmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Keitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Soddemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Wilker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory C.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary D.","family":"Hammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Daser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos E.","family":"Bechrakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina-Eva","family":"G\u00f6rtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Eckstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ando.2018.09.002","article-title":"Graves\u2019 disease: Introduction, epidemiology, endogenous and environmental pathogenic factors","volume":"79","author":"W\u00e9meau","year":"2018","journal-title":"Ann Endocrinol (Paris)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-017-1306-5","article-title":"Epidemiology, management and outcomes of Graves\u2019 disease-real life data","volume":"56","author":"Hussain","year":"2017","journal-title":"Endocrine"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2018.18","article-title":"Global epidemiology of hyperthyroidism and hypothyroidism","volume":"14","author":"Taylor","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-020-0184-y","article-title":"Graves\u2019 disease","volume":"6","author":"Davies","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1555762","article-title":"Current insights into the pathogenesis of graves\u2019 Ophthalmopathy","volume":"47","author":"Bahn","year":"2015","journal-title":"Horm Metab Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.21.2.0393","article-title":"Management of Graves\u2019 ophthalmopathy: reality and perspectives","volume":"21","author":"Bartalena","year":"2000","journal-title":"Endocr Rev"},{"key":"B7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.exer.2015.02.007","article-title":"Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves\u2019 ophthalmopathy","volume":"142","author":"Dik","year":"2016","journal-title":"Exp Eye Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2813","article-title":"Thyrotropin receptor autoantibodies are independent risk factors for Graves\u2019 ophthalmopathy and help to predict severity and outcome of the disease","volume":"91","author":"Eckstein","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.12.6348","article-title":"Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves\u2019 disease is mediated through the insulin-like growth factor I receptor pathway","volume":"170","author":"Pritchard","year":"2003","journal-title":"J Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.5.3281","article-title":"Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves\u2019 disease may carry functional consequences for disease pathogenesis","volume":"178","author":"Douglas","year":"2007","journal-title":"J Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.8.5768","article-title":"B cells from patients with Graves\u2019 disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis","volume":"181","author":"Douglas","year":"2008","journal-title":"J Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/en.2017-00528","article-title":"TSH\/IGF-1 receptor cross-talk rapidly activates extracellular signal-regulated kinases in multiple cell types","volume":"158","author":"Krieger","year":"2017","journal-title":"Endocrinology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00066","article-title":"Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy","volume":"40","author":"Smith","year":"2019","journal-title":"Endocr Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9394(14)70276-4","article-title":"Clinical features of Graves\u2019 ophthalmopathy in an incidence cohort","volume":"121","author":"Bartley","year":"1996","journal-title":"Am J Ophthalmol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3566","article-title":"Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves\u2019 disease immunoglobins","volume":"100","author":"Krieger","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.09.89","article-title":"Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor","volume":"1","author":"Mulvihill","year":"2009","journal-title":"Future Med Chem"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1038\/s41467-019-12564-0","article-title":"Structural basis of the activation of type 1 insulin-like growth factor receptor","volume":"10","author":"Li","year":"2019","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1211473","article-title":"Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease","volume":"14","author":"Gulbins","year":"2023","journal-title":"Front Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1016\/j.cell.2022.05.020","article-title":"Bone marrow hematopoiesis drives multiple sclerosis progression","volume":"185","author":"Shi","year":"2022","journal-title":"Cell"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13044-018-0046-9","article-title":"Role of the T and B lymphocytes in pathogenesis of autoimmune thyroid diseases","volume":"11","author":"Rydzewska","year":"2018","journal-title":"Thyroid Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2022.101620","article-title":"Pathophysiology of thyroid-associated orbitopathy","volume":"37","author":"Lee","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1006\/clin.1994.1169","article-title":"Immunohistochemical staining of retrobulbar adipose tissue in Graves\u2019 ophthalmopathy","volume":"73","author":"Kahaly","year":"1994","journal-title":"Clin Immunol Immunopathol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2003.035915","article-title":"Thyroid associated ophthalmopathy: evidence for CD4(+) gammadelta T cells; de novo differentiation of RFD7(+) macrophages, but not of RFD1(+) dendritic cells; and loss of gammadelta and alphabeta T cell receptor expression","volume":"88","author":"Eckstein","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0754","article-title":"Fingolimod improves the outcome of experimental graves\u2019 Disease and associated orbitopathy by modulating the autoimmune response to the thyroid-stimulating hormone receptor","volume":"29","author":"Pl\u00f6hn","year":"2019","journal-title":"Thyroid"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1210\/en.2015-1829","article-title":"Comparative assessment of female mouse model of graves\u2019 Orbitopathy under different environments, accompanied by proinflammatory cytokine and T-cell responses to thyrotropin hormone receptor antigen","volume":"157","author":"Berchner-Pfannschmidt","year":"2016","journal-title":"Endocrinology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"13096","DOI":"10.1038\/s41598-018-31253-4","article-title":"Graves\u2019 orbitopathy occurs sex-independently in an autoimmune hyperthyroid mouse model","volume":"8","author":"Schl\u00fcter","year":"2018","journal-title":"Sci Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2021.0464","article-title":"An early wave of macrophage infiltration intertwined with antigen-specific proinflammatory T cells and browning of adipose tissue characterizes the onset of orbital inflammation in a mouse model of graves\u2019 Orbitopathy","volume":"32","author":"Philipp","year":"2022","journal-title":"Thyroid"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01715-w","article-title":"The universal stem cell","volume":"36","author":"Quesenberry","year":"2022","journal-title":"Leukemia"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-804280-9.00009-3","article-title":"Meningioma: Signaling pathways and tumor growth","volume":"169","author":"Burnett","year":"2020","journal-title":"Handb Clin Neurol"},{"key":"B30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/B978-0-12-802734-9.00005-6","article-title":"HSC Niche: regulation of mobilization and homing","volume-title":"Biology and engineering of stem cell niches","author":"Wasnik","year":"2017"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0113014","article-title":"Ly6 family proteins in neutrophil biology","volume":"94","author":"Lee","year":"2013","journal-title":"J Leukoc Biol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/qjmed\/95.1.3","article-title":"Osteopontin\u2013a molecule for all seasons","volume":"95","author":"Mazzali","year":"2002","journal-title":"QJM"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1126\/science.287.5454.860","article-title":"Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity","volume":"287","author":"Ashkar","year":"2000","journal-title":"Science"},{"key":"B34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.clinbiochem.2018.07.003","article-title":"The multiple functions and mechanisms of osteopontin","volume":"59","author":"Icer","year":"2018","journal-title":"Clin Biochem"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1615\/critrevimmunol.v32.i1.30","article-title":"Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease","volume":"32","author":"Iyer","year":"2012","journal-title":"Crit Rev Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2310\/JIM.0b013e31819aaa76","article-title":"The anti-inflammatory effects of prostaglandins","volume":"57","author":"Scher","year":"2009","journal-title":"J Investig Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1146\/annurev.nutr.22.110801.140547","article-title":"Regulation of enzymes of the urea cycle and arginine metabolism","volume":"22","author":"Morris","year":"2002","journal-title":"Annu Rev Nutr"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/bj3360001","article-title":"Arginine metabolism: nitric oxide and beyond","volume":"336","author":"Wu","year":"1998","journal-title":"Biochem J"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.617699","article-title":"Inhibition of arginase 1 liberates potent T cell immunostimulatory activity of human neutrophil granulocytes","volume":"11","author":"Vonwirth","year":"2021","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1152\/physrev.00022.2002","article-title":"Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells","volume":"83","author":"Mann","year":"2003","journal-title":"Physiol Rev"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/s1471-4906(03)00132-7","article-title":"L-arginine metabolism in myeloid cells controls T-lymphocyte functions","volume":"24","author":"Bronte","year":"2003","journal-title":"Trends Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/nri1668","article-title":"Regulation of immune responses by L-arginine metabolism","volume":"5","author":"Bronte","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063521","article-title":"Cytotoxicity of tumor antigen specific human T cells is unimpaired by arginine depletion","volume":"8","author":"Munder","year":"2013","journal-title":"PloS One"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.112840","article-title":"Arginase: An emerging and promising therapeutic target for cancer treatment","volume":"149","author":"Niu","year":"2022","journal-title":"BioMed Pharmacother"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2017.11.005","article-title":"mTOR inhibitor rapamycin induce polymorphonuclear myeloid-derived suppressor cells mobilization and function in protecting against acute graft-versus-host disease after bone marrow transplantation","volume":"187","author":"Lin","year":"2018","journal-title":"Clin Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.86","article-title":"The mTOR signal regulates myeloid-derived suppressor cells differentiation and immunosuppressive function in acute kidney injury","volume":"8","author":"Zhang","year":"2017","journal-title":"Cell Death Dis"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-022-01862-y","article-title":"Sirolimus as a second-line treatment for Graves\u2019 orbitopathy","volume":"45","author":"Lanzolla","year":"2022","journal-title":"J Endocrinol Invest"},{"key":"B49","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.tips.2015.03.006","article-title":"Arginase: an old enzyme with new tricks","volume":"36","author":"Caldwell","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.129756","article-title":"Regulatory T cells use arginase 2 to enhance their metabolic fitness in tissues","volume":"4","author":"Lowe","year":"2019","journal-title":"JCI Insight"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2018.07.010","article-title":"Human T cells modulate myeloid-derived suppressor cells through a TNF-\u03b1-mediated mechanism","volume":"202","author":"Bauswein","year":"2018","journal-title":"Immunol Lett"},{"key":"B52","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1016\/j.cell.2021.06.007","article-title":"Polyamine metabolism is a central determinant of helper T cell lineage fidelity","volume":"184","author":"Puleston","year":"2021","journal-title":"Cell"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1177\/014860710102500123","article-title":"Effects of L-arginine on the proliferation of T lymphocyte subpopulations","volume":"25","author":"Ochoa","year":"2001","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/137.6.1681S","article-title":"Arginine and immunity","volume":"137","author":"Popovic","year":"2007","journal-title":"J Nutr"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-018-0279-9","article-title":"The involvement of T cell pathogenesis in thyroid-associated ophthalmopathy","volume":"33","author":"Huang","year":"2019","journal-title":"Eye (Lond)"},{"key":"B56","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/ni1415","article-title":"Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells","volume":"8","author":"Hur","year":"2007","journal-title":"Nat Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.048298","article-title":"Osteopontin\/Eta-1 upregulated in Crohn\u2019s disease regulates the Th1 immune response","volume":"54","author":"Sato","year":"2005","journal-title":"Gut"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.62.12.18","article-title":"The potential role of osteopontin in the pathogenesis of graves\u2019 Ophthalmopathy","volume":"62","author":"Lou","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgl016","article-title":"Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN","volume":"27","author":"Packer","year":"2006","journal-title":"Carcinogenesis"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23261","article-title":"Interleukin-6 activates PI3K\/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival","volume":"122","author":"Wegiel","year":"2008","journal-title":"Int J Cancer"},{"key":"B61","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.coemr.2018.01.007","article-title":"Thyroid stimulating hormone (TSH)\/insulin-like growth factor 1 (IGF1) receptor cross-talk in human cells","volume":"2","author":"Krieger","year":"2018","journal-title":"Curr Opin Endocr Metab Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.6.4397","article-title":"Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves\u2019 disease","volume":"181","author":"Tsui","year":"2008","journal-title":"J Immunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40168-020-00952-4","article-title":"INDIGO consortium. Modulating gut microbiota in a mouse model of Graves\u2019 orbitopathy and its impact on induced disease","volume":"9","author":"Moshkelgosha","year":"2021","journal-title":"Microbiome"},{"key":"B64","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1055\/s-0035-1555956","article-title":"Modeling graves\u2019 Orbitopathy in experimental graves\u2019 Disease","volume":"47","author":"Banga","year":"2015","journal-title":"Horm Metab Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02311-7","article-title":"Lessons from mouse models of Graves\u2019 disease","volume":"68","author":"Eckstein","year":"2020","journal-title":"Endocrine"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1252727\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T03:12:08Z","timestamp":1695611528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1252727\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,22]]},"references-count":65,"alternative-id":["10.3389\/fendo.2023.1252727"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1252727","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,22]]},"article-number":"1252727"}}